Results 11 to 20 of about 60,318 (267)
Pharmaceutical pricing and reimbursement information (PPRI): evolution and impact of a policy network over two decades [PDF]
Journal of Pharmaceutical Policy and PracticeBackground In 2005, the Pharmaceutical Pricing and Reimbursement Information (PPRI) network of public authorities was established to offer a platform for information exchange among authorities responsible for pharmaceutical pricing and reimbursement. The
Sabine Vogler +3 more
doaj +2 more sources
Negative prices in network pricing games
Operations Research Letters, 2022 In a Stackelberg network pricing game, a leader sets prices for a given subset of edges so as to maximize profit, after which one or multiple followers choose a shortest path from their source to sink. We study the counter-intuitive phenomenon that the use of negative prices by the leader may in fact increase his profit.
Andrés Cristi, Marc Schröder 0002
openaire +4 more sources
Comparison of Cardiovascular Medicines Prices in Four European Countries
Frontiers in Public Health, 2020 The aim of the current study was to compare pricing methodologies at the manufacturer, wholesale, and retail levels, and to estimate the price differences of AT1-receptor blockers (sartans), Angiotensin-converting enzyme (ACE)—inhibitors, and their fixed-
Zornitsa Mitkova +8 more
doaj +1 more source
Antibiotics, 2022 Point-of-care diagnostic tests for community-acquired acute respiratory tract infections (CA-ARTI) can support doctors by improving antibiotic prescribing.
Sabine Vogler, Friederike Windisch
doaj +1 more source
Commodity Price Forecasts, Futures Prices, and Pricing Models [PDF]
Management Science, 2019 Even though commodity-pricing models have been successful in fitting the term structure of futures prices and its dynamics, they do not generate accurate true distributions of spot prices. This paper develops a new approach to calibrate these models using not only observations of oil futures prices, but also analysts’ forecasts of oil spot prices.
Gonzalo Cortazar +3 more
openaire +2 more sources
Health and Quality of Life Outcomes, 2020 Background A Task Force from the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) provides recommendations on how to systematically identify and appraise health state utility (HSU) weights for cost-effectiveness analyses.
Jacie T. Cooper +5 more
doaj +1 more source
Ramsey prices, average cost prices and price sustainability [PDF]
International Journal of Industrial Organization, 1986 Abstract We study the relationship between sustainable and average cost prices in the multiproduct case. It is shown that for the case where costs are separable only average cost prices can be sustainable even if demands are interdependent. As for the non-separable cost case the notion of average cost prices is axiomatically defined as an extension ...
Leonard J. Mirman +2 more
openaire +2 more sources
New tariff regulation for natural monopolies: what should it be?
Стратегические решения и риск-менеджмент, 2017 For the last several years, the Russian Federation has been artificially restraining the growth of tariffs for the services of natural monopolies. A simple decision, which is taken hastily a few years ago as a short-term anti-crisis measure, has every ...
I. A. Dolmatov +2 more
doaj +1 more source
Cost Effectiveness and Resource Allocation, 2020 Background Several governments apply the policy of external price referencing (EPR), which considers the prices of a medicine in one or more other countries for the purpose of setting the price in the own country.
Sabine Vogler +2 more
doaj +1 more source
Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines
Journal of Market Access & Health Policy, 2017 Introduction: Health technology assessment (HTA) in Poland supports reimbursement decisions via the Polish HTA Agency (AOTMiT), whose guidelines were updated in 2016.
Krzysztof Lach +3 more
doaj +1 more source